Home
Dear visitor,
HIV/AIDS remains a severe problem in the world, particularly in Africa. The current standard therapy for AIDS is based on cocktails of drugs. This treatment is associated with side effects and is almost unaffordable for the patients living in sub-Saharan Africa. Moreover, incomplete suppression of HIV replication results in emergence of drug-resistant strains. Therefore, a continued research effort is required to develop more potent, cheaper and less toxic antivirals.
The insight has grown that HIV requires multiple cellular proteins to serve as co-factors for viral replication. Our over-all objective is to develop novel treatment strategies by targeting cellular proteins required for HIV trafficking, nuclear import and integration. We predict that such drugs may elicit less drug resistance. To reach this objective we formed a multidisciplinary consortium composed of 3 biologists/virologists, 3 medicinal chemists, 1 virologist from South Africa, 1 structural biologist and 1 pharmaceutical company (left in 2010).
With this project we will significantly enhance basic understanding of HIV and contribute to the health situation of many people worldwide.
Enjoy this website and please contact us if you need more information.
The
Consortium
